Leflunomide improves quality of life in rheumatoid arthritis

Scandinavian Journal of Rheumatology, Supplement

Volumn 28, Issue 112, 1999, Pages 23-29

  Scott, D L ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

DMARDs; Functional disability; Health assessment questionnaires; Leflunomide; Methotrexate; Randomized trials; Sulfasalazine

Indexed keywords

ANTIRHEUMATIC AGENT; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; ISOXAZOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EUROPE; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORTH AMERICA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; WORK DISABILITY; MIDDLE AGED;

ACTIVITIES OF DAILY LIVING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; QUALITY OF LIFE; SULFASALAZINE;

EID: 0033386198     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097499750042254-1     Document Type: Article

References (22)

1. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
2. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum 1983;26:1346-53.
3. Bakker C, van der Linden S, van Santen-Hoeufft M. Bolwijn P, Hidding A. Problem elicitation to assess patient priorities in ankylosing spondylitis and fibromyalgia. J Rheumatol 1995;22:1304-10.
4. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
5. Talamo J, Frater A, Gallivan S, Young A. Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis. Br J Rheumatol 1997;36:463-9.
6. Ruta DA, Hurst NP, Kind P, Hunter M, Stubbings A, Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol 1998;37:425-36.
7. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J, Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying anti-rheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
8. Bombardier C, Ware J, Russel IJ, Larson M, Chalmers A, Read JL, et al. Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med 1986;81:565-77.
9. Tugwell P, Bombardier C, Buchanan WW, Goldsmith C, Grace E, Bennett K, et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med 1990;150:59-62.
10. Bombardier C, Buchbinder R, Tugwell P. Efficacy of cyclosporin A in rheumatoid arthritis: Long-term follow-up data and the effect on quality of life. Scand J Rheumatol 1992;21:29-33.
11. Rückemann K, Fairbanks LD, Carrey LA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T lymphocytes from healthy humans. J Biol Chem 1998;273:21682-91.
12. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998:25 Suppl 53:20-6.
13. Kremer JM. Methotrexate and leflunomide: Biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999;29:14-26.
14. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J. et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603.
15. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Loew-Friedrich I, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet. 1999;353:259-66.
16. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch Int Med 1999:159: in press.
17. Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998;57:88-93.
18. Capell HA, Maiden N, Madhok R, Hampson R, Thomson EA. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine. J Rheumatol 1998;25:1880-6.
19. Wells GA, Tugwell P, Kraag GR, Baker PRA, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
20. Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R, et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 1997;24:9-13.
21. Anonymous. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med 1995;98:156-68.
22. van Leeuwen MA, van der Heijde DMFM, van Rijswijk MH, Houtman PM, van Riel PLCM, van de Putte LBA, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-9.